RxDoctor Payments Data

Charles Port, DO

Neurology · New Bern, NCNPI 1285169763

Payments from drug & device makers

$2,648in general payments, 2019–2025

Across 138 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lundbeck LLC$363
  • AstraZeneca$154
  • Grifols USA, LLC$150
  • Johnson & Johnson$139
  • Neurelis, Inc.$130
  • AbbVie$130
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$2,60198%
  • Education$482%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,648 in reported general payments places this provider in the 55th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,275,929
Medicare patients
1,078
Services billed
40,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcrevusOcrelizumab12$497,922
IngrezzaValbenazine Tosylate15$118,474
FingolimodFingolimod Hcl31$92,955
Nurtec OdtRimegepant Sulfate60$86,196
UbrelvyUbrogepant44$58,191
Aimovig AutoinjectorErenumab-Aooe61$54,660
Ajovy AutoinjectorFremanezumab-Vfrm37$39,756
BriviactBrivaracetam17$38,035
Emgality PenGalcanezumab-Gnlm32$30,663
RexultiBrexpiprazole24$29,471
Oxtellar XrOxcarbazepine12$20,474
Lacosamide106$18,410
QuliptaAtogepant17$18,138
RytaryCarbidopa/Levodopa11$16,227
Carbidopa-LevodopaCarbidopa/Levodopa550$13,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$40$118,47415 claims
PfizerNurtec Odt$19$86,19660 claims
AbbVieUbrelvy, Qulipta$130$76,32961 claims
UCB, Inc.Briviact$52$38,03517 claims
Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil$76$18,73549 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 566 neurology providers in North Carolina.

Other neurology in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →